Raia Drogasil S.A.
RADLYOTCHealthcare● Active
$3.52
+$0.08(+2.33%)
Market Cap$6.2B
P/E Ratio—
52W High$5.342
52W Low$2.22
Raia Drogasil S.A. (RADLY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RADLY · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$0.02
Est. $0.03 · -45.0%
Revenue
$2.43B
Est. $2.36B · +3.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
RADLY reports quarterly as a OTC-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $0.05 | — | — | — | $2.26B | — |
| ▼ Q2 FY2026 | May 6, 2026 | $0.03 | $0.02 | -45.0% | $2.43B | $2.36B | +3.0% |
| ▼ Q1 FY2026 | Mar 3, 2026 | $0.04 | $0.03 | -16.0% | $2.33B | $2.29B | +1.8% |
| ▲ Q3 FY2025 | Aug 4, 2025 | $0.03 | $0.04 | +41.4% | $1.99B | $2.12B | -5.9% |
| ▼ Q2 FY2025 | May 5, 2025 | $0.02 | $0.02 | -28.5% | $1.72B | $1.81B | -4.8% |
| ▲ Q1 FY2025 | Feb 25, 2025 | $0.03 | $0.03 | +26.1% | $1.63B | $1.74B | -6.3% |
| ▲ Q4 FY2024 | Nov 5, 2024 | $0.03 | $0.04 | +22.7% | $1.83B | $1.82B | +0.3% |
| ▼ Q3 FY2024 | Aug 6, 2024 | $0.04 | $0.04 | -13.3% | $1.73B | $1.83B | -5.3% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Miss
EPS Actual
$0.02
EPS Est.
$0.03
EPS Surpr.
-45.0%
Revenue
$2.43B
Q1 FY2026
Mar 3, 2026Miss
EPS Actual
$0.03
EPS Est.
$0.04
EPS Surpr.
-16.0%
Revenue
$2.33B
Q3 FY2025
Aug 4, 2025Beat
EPS Actual
$0.04
EPS Est.
$0.03
EPS Surpr.
+41.4%
Revenue
$1.99B
Q2 FY2025
May 5, 2025Miss
EPS Actual
$0.02
EPS Est.
$0.02
EPS Surpr.
-28.5%
Revenue
$1.72B
Q1 FY2025
Feb 25, 2025Beat
EPS Actual
$0.03
EPS Est.
$0.03
EPS Surpr.
+26.1%
Revenue
$1.63B
Q4 FY2024
Nov 5, 2024Beat
EPS Actual
$0.04
EPS Est.
$0.03
EPS Surpr.
+22.7%
Revenue
$1.83B
Q3 FY2024
Aug 6, 2024Miss
EPS Actual
$0.04
EPS Est.
$0.04
EPS Surpr.
-13.3%
Revenue
$1.73B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.36 | $0.36 | $0.38 | 1 |
| Q3 FY2027 | $0.35 | $0.35 | $0.37 | 1 |
| Q2 FY2027 | $0.33 | $0.33 | $0.34 | 1 |
| Q1 FY2027 | $0.23 | $0.24 | $0.25 | 1 |
| Q4 FY2026 | $0.29 | $0.30 | $0.31 | 1 |
| Q3 FY2026 | $0.27 | $0.27 | $0.28 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $11.2B | $11.4B | $11.8B | 1 |
| Q3 FY2027 | $11.1B | $11.3B | $11.6B | 2 |
| Q2 FY2027 | $11.0B | $11.2B | $11.5B | 2 |
| Q1 FY2027 | $10.9B | $11.1B | $11.4B | 1 |
| Q4 FY2026 | $12.4B | $12.6B | $13.0B | 2 |
| Q3 FY2026 | $11.8B | $12.0B | $12.4B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 6, 2026 | -45.0% | $4.62 | $4.55 | -1.52% |
| ▼ Q1 FY2026 | Mar 3, 2026 | -16.0% | $4.70 | $4.71 | +0.21% |
| ▲ Q3 FY2025 | Aug 4, 2025 | +41.4% | $2.61 | $2.79 | +6.90% |
| ▼ Q2 FY2025 | May 5, 2025 | -28.5% | $3.29 | $3.46 | +5.17% |
| ▲ Q1 FY2025 | Feb 25, 2025 | +26.1% | $3.22 | $3.22 | +0.00% |
| ▲ Q4 FY2024 | Nov 5, 2024 | +22.7% | $4.49 | $4.16 | -7.35% |
| ▼ Q3 FY2024 | Aug 6, 2024 | -13.3% | $5.15 | $5.37 | +4.27% |
| ▼ Q2 FY2024 | May 7, 2024 | -21.5% | $5.00 | $5.00 | +0.00% |
Q2 FY2026-1.52%
Report Date
May 6, 2026
EPS Beat/Miss
-45.0%
Price Before
$4.62
Price After
$4.55
Q1 FY2026+0.21%
Report Date
Mar 3, 2026
EPS Beat/Miss
-16.0%
Price Before
$4.70
Price After
$4.71
Q3 FY2025+6.90%
Report Date
Aug 4, 2025
EPS Beat/Miss
+41.4%
Price Before
$2.61
Price After
$2.79
Q2 FY2025+5.17%
Report Date
May 5, 2025
EPS Beat/Miss
-28.5%
Price Before
$3.29
Price After
$3.46
Q1 FY2025+0.00%
Report Date
Feb 25, 2025
EPS Beat/Miss
+26.1%
Price Before
$3.22
Price After
$3.22
Q4 FY2024-7.35%
Report Date
Nov 5, 2024
EPS Beat/Miss
+22.7%
Price Before
$4.49
Price After
$4.16
Q3 FY2024+4.27%
Report Date
Aug 6, 2024
EPS Beat/Miss
-13.3%
Price Before
$5.15
Price After
$5.37
Q2 FY2024+0.00%
Report Date
May 7, 2024
EPS Beat/Miss
-21.5%
Price Before
$5.00
Price After
$5.00
Avg Beat Reaction-0.15%
Avg Miss Reaction+1.63%
Beat Rate3 / 8 quarters
Largest Move-7.35% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RADLY ends December
Raia Drogasil S.A. (RADLY) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $0.02 — missing the analyst consensus of $0.03 by -45.0%. The next RADLY earnings date is expected around September 1, 2026.
Each quarter, investors track RADLY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RADLY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RADLY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RADLY earnings · 5 questionsRaia Drogasil S.A.'s next earnings report is expected around September 1, 2026. RADLY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RADLY historically reports after market close (AMC).
RADLY earnings datewhen is RADLY earningsRADLY next earnings datewhen does RADLY report earningsRADLY earnings calendar
▸ Source: FMP · Raia Drogasil S.A. SEC filings · US GAAP · Raia Drogasil S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026